Free Trial

Cencora (COR) Stock Forecast & Price Target

Cencora logo
$298.07 -4.43 (-1.46%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$296.86 -1.21 (-0.41%)
As of 08:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
9

Based on 11 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 2 have given a hold rating, and 9 have given a buy rating for COR.

Consensus Price Target

$306.33
2.77% Upside
According to the 11 analysts' twelve-month price targets for Cencora, the average price target is $306.33. The highest price target for COR is $355.00, while the lowest price target for COR is $275.00. The average price target represents a forecasted upside of 2.77% from the current price of $298.07.
Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

Sign Up

COR Analyst Ratings Over Time

TypeCurrent Forecast
7/9/24 to 7/9/25
1 Month Ago
6/9/24 to 6/9/25
3 Months Ago
4/10/24 to 4/10/25
1 Year Ago
7/10/23 to 7/9/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$306.33$306.91$280.20$236.10
Forecasted Upside2.77% Upside8.09% Upside0.42% Upside6.17% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cencora Stock vs. The Competition

TypeCencoraMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.80
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.77% Upside9,164.86% Upside10.40% Upside
News Sentiment Rating
Positive News

See Recent COR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/30/2025Jefferies Financial Group
2 of 5 stars
Jonathan Petersen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$275.00 ➝ $300.00+0.55%
6/3/2025Wells Fargo & Company
3 of 5 stars
Stephen Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$274.00 ➝ $337.00+15.37%
5/8/2025Citigroup
3 of 5 stars
Michael Rollins
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$330.00 ➝ $355.00+23.80%
5/8/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Rodgers
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$314.00 ➝ $350.00+15.12%
4/29/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kevin Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$298.00 ➝ $335.00+16.26%
4/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Erin Wright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$288.00+1.22%
4/11/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Funk
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$270.00 ➝ $285.00+2.14%
2/6/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
John Belton
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$270.00 ➝ $280.00+12.80%
1/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lisa Gill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$289.00 ➝ $301.00+21.13%
12/4/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Outperform$280.00+11.98%
11/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$263.00 ➝ $290.00+18.18%
10/7/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$277.00 ➝ $275.00+25.03%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/7/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$205.00 ➝ $215.00+15.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:00 AM ET.


Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 7, 2025. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Cencora, Inc.:

  • The current stock price is around $302, reflecting a strong market position and investor confidence in the company's growth potential.
  • Institutional investors own a significant majority of the stock, indicating strong support and confidence from large financial entities.
  • Recent insider transactions show that key executives are actively managing their holdings, which can signal confidence in the company's future performance.
  • Cencora, Inc. has demonstrated a solid market capitalization of approximately $58.62 billion, suggesting a stable financial foundation for growth.
  • The company has a relatively low beta of 0.57, indicating that its stock is less volatile compared to the market, which can be appealing for risk-averse investors.

Cencora
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Cencora, Inc. for these reasons:

  • Recent insider sales, including significant transactions by the chairman and CEO, may raise concerns about the company's future outlook and management's confidence.
  • There has been a notable decrease in positions held by some institutional investors, which could indicate a lack of confidence in the stock's short-term performance.
  • The stock has experienced fluctuations, with a 52-week high of $309.35 and a low of $218.65, suggesting potential volatility that could deter some investors.
  • The price-to-earnings (P/E) ratio of around 35.08 may be considered high, indicating that the stock could be overvalued compared to its earnings, which might concern value investors.
  • Recent reports indicate that some hedge funds have reduced their stakes, which could signal a bearish sentiment among certain market participants.

COR Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $306.33, with a high forecast of $355.00 and a low forecast of $275.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COR shares.

According to analysts, Cencora's stock has a predicted upside of 2.77% based on their 12-month stock forecasts.

Over the previous 90 days, Cencora's stock had 1 upgrade by analysts.

Cencora has been rated by research analysts at Bank of America, Citigroup, Jefferies Financial Group, Morgan Stanley, Robert W. Baird, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Cencora more than other "medical" companies. The consensus rating score for Cencora is 2.82 while the average consensus rating score for "medical" companies is 2.80. Learn more on how COR compares to other companies.


This page (NYSE:COR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners